23-Valent Pneumococcal Polysaccharide Vaccine Market

List of Tables

The 23-Valent Pneumococcal Polysaccharide Vaccine Market is projected to grow by USD 1.77 billion at a CAGR of 7.72% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.05 billion
Estimated Year [2026]	USD 1.13 billion
Forecast Year [2032]	USD 1.77 billion
CAGR (%)	7.72%

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is designed to protect against invasive disease and pneumonia associated with 23 Streptococcus pneumoniae serotypes. Its use is shaped by age, underlying medical conditions, prior vaccination, national immunization policy, and recommendations from public-health authorities. Because protection and scheduling requirements differ across populations, effective deployment depends on clinically appropriate patient assessment and alignment with local guidance.

Transformative Shifts in Pneumococcal Prevention and Delivery

Pneumococcal prevention is shifting toward risk-based vaccination pathways that distinguish older adults from people with immunocompromising conditions, chronic diseases, or other elevated risks. Many jurisdictions increasingly evaluate PPSV23 alongside pneumococcal conjugate vaccines, with product sequence and timing determined by national recommendations. Delivery is also being influenced by routine adult immunization, pharmacy-based services, electronic reminders, strengthened procurement systems, and efforts to improve access among underserved populations.

How Artificial Intelligence Is Influencing Pneumococcal Vaccination

Artificial intelligence can support pneumococcal vaccination programs by identifying patients who may be eligible from electronic health records, reconciling prior immunization histories, and prioritizing outreach according to age and clinical risk. Analytics may also help public-health teams identify geographic or demographic gaps, improve appointment planning, and monitor safety signals. These applications require validated clinical rules, representative data, privacy safeguards, human oversight, and clear separation between decision support and prescribing or administration decisions.

Regional Insights Across Six Public-Health Environments

North America generally benefits from established adult immunization guidance, broad healthcare infrastructure, and multiple vaccination channels, while access and uptake can still vary by insurance status, geography, and trust. Europe combines strong public-health capacity with differing national schedules, reimbursement arrangements, and recommendations across countries. Asia-Pacific includes mature immunization systems alongside rapidly expanding healthcare access, creating varied implementation needs. Latin America continues to strengthen adult and risk-based vaccination while addressing affordability, primary-care reach, and supply continuity. The Middle East shows substantial variation in policy, healthcare capacity, and expatriate populations. Africa's priorities include improving adult-risk identification, cold-chain and primary-care capacity, financing, and awareness, particularly for people with comorbidities and those living with HIV.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN members face diverse health-system capabilities and national recommendations, making regional coordination, reliable procurement, and adult-risk communication especially important. BRICS countries span large and varied populations, with opportunities to strengthen surveillance, domestic production capabilities, and equitable access while adapting policies to local disease burdens. The European Union benefits from coordinated scientific and regulatory structures, but vaccination schedules and funding decisions remain primarily national. G7 systems typically have stronger adult immunization infrastructure and data capacity, with persistent challenges in reaching hesitant or medically underserved groups. GCC countries can leverage centralized procurement and modern healthcare networks, while NATO members may place additional emphasis on continuity of essential health services and protection of medically vulnerable populations during emergencies.

Country Insights: Policy and Delivery Considerations

Australia, Canada, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States have established vaccination systems, but eligibility criteria, sequencing with conjugate vaccines, funding, and delivery settings differ by jurisdiction. Brazil, China, India, Mexico, Russia, and South Korea combine substantial healthcare capabilities with regional variation in access, surveillance, and adult immunization implementation. Across these countries, practical priorities include maintaining accurate vaccination records, integrating recommendations into primary care, improving outreach to older adults and high-risk patients, and ensuring consistent product availability. National decisions should follow current guidance from the relevant health authorities rather than assuming that practices are transferable across borders.

Actionable Priorities for Industry and Public-Health Leaders

Leaders should align product education, clinical decision support, and patient communications with current national recommendations, especially where PPSV23 is used within a broader pneumococcal vaccination sequence. Strengthening partnerships with primary-care practices, pharmacies, hospitals, and community organizations can improve identification and reach of eligible adults. Investments in interoperable immunization records, reminder systems, workforce training, and transparent safety communication can reduce missed opportunities. Procurement planning should include supply resilience, equitable allocation, appropriate storage, and monitoring of administration data, while evaluation should focus on coverage among priority groups and reduction of preventable disease rather than volume alone.

Research Methodology: Evidence-Based Executive Synthesis

This executive summary uses the supplied market definition-23-valent pneumococcal polysaccharide vaccine-and synthesizes established public-health and clinical considerations without introducing market estimates, forecasts, shares, or company-specific claims. The analysis is structured around vaccine use, policy evolution, healthcare delivery, digital tools, geography, population groupings, and country implementation. Interpretations should be validated against current guidance from national immunization authorities, recognized public-health agencies, regulatory documents, peer-reviewed evidence, and local epidemiological surveillance because recommendations and product availability can change.

Conclusion: Improving Protection Through Coordinated Implementation

PPSV23 remains an important component of pneumococcal disease prevention for selected adults and high-risk populations when used according to applicable clinical guidance. Its public-health value depends on more than vaccine availability: accurate eligibility assessment, appropriate sequencing, reliable delivery, informed acceptance, and sustained monitoring are all essential. Coordinated action across health systems, community providers, digital infrastructure, and procurement networks can help close immunization gaps while preserving patient safety and policy consistency.

Product Code: MRR-562C14C35C96

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Product Type

7.1. Introduction
7.2. Branded Vaccine
7.3. Generic Vaccine

8. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Formulation

8.1. Introduction
8.2. Auto-disable Prefilled Syringe
8.3. Multi Dose Vial
8.4. Single Dose Glass Vial
8.5. Single Dose Prefilled Syringe

9. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Route Of Administration

9.1. Introduction
9.2. Intramuscular Injection
9.3. Subcutaneous Injection

10. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Packaging

10.1. Introduction
10.2. Multi-Dose Packaging
10.3. Single-Dose Packaging
10.4. Unit Dose Packs

11. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Risk Group

11.1. Introduction
11.2. Chronic Disease Patients
- 11.2.1. Chronic Heart Disease
- 11.2.2. Chronic Lung Disease
- 11.2.3. Diabetes Mellitus
- 11.2.4. Kidney Disease
- 11.2.5. Liver Disease
11.3. Elderly Population
11.4. Healthcare Workers
11.5. Immunocompromised Individuals
- 11.5.1. Asplenic Individuals
- 11.5.2. Cancer & Chemotherapy Patients
- 11.5.3. HIV Patients
- 11.5.4. Organ Transplant Recipients
11.6. Smokers
11.7. Travelers

12. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by End User

12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Clinics
- 12.3.1. Primary Care Clinics
- 12.3.2. Specialty Clinics
12.4. Homecare Settings
12.5. Hospitals
- 12.5.1. Government Hospitals
- 12.5.2. Private Hospitals
12.6. Research Institutes
12.7. Vaccination Centers

13. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Sales Channel

13.1. Introduction
13.2. Offline
13.3. Online

14. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Region

14.1. Introduction
14.2. Asia-Pacific
14.3. Europe
14.4. North America
14.5. Africa
14.6. Latin America
14.7. Middle East

15. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Group

15.1. Introduction
15.2. NATO
15.3. G7
15.4. European Union
15.5. BRICS
15.6. ASEAN
15.7. GCC

16. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Country

16.1. Introduction
16.2. United States
16.3. China
16.4. Germany
16.5. Japan
16.6. India
16.7. United Kingdom
16.8. France
16.9. Canada
16.10. Australia
16.11. Italy
16.12. South Korea
16.13. Russia
16.14. Brazil
16.15. Mexico
16.16. Spain

17. Competitive Landscape

17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
- 17.2.1. Concentration Ratio (CR)
- 17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025

18. Company Profiles

18.1. Beijing Minhai Biotechnology Co Ltd.
18.2. Bharat Biotech International Ltd
18.3. Biological E Limited
18.4. Chengdu Institute of Biological Products Co Ltd.
18.5. Chongqing Zhifei Biological Products Co Ltd.
18.6. CSL Ltd.
18.7. Dr Reddys Laboratories Limited
18.8. Lanzhou Institute of Biological Products Co Ltd.
18.9. Lupin Ltd.
18.10. Mankind Pharma Ltd.
18.11. Merck Sharp & Dohme LLC
18.12. Novavax Inc.
18.13. Panacea Biotec Ltd
18.14. Sanofi Pasteur SA
18.15. Serum Institute of India Pvt Ltd
18.16. Shanghai Institute of Biological Products Co Ltd.
18.17. Sinopharm Group Co Ltd.
18.18. Sinovac Biotech Ltd.
18.19. SK Bioscience Co Ltd.
18.20. Yuxi Walvax Biotechnology Co Ltd.

19. Key Experts